Physician profile
Jayashree S John
NPI 1003012915
$2,815.13
in general payments reported to CMS, 2019-2025
22 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $526 · 2021: $298 · 2022: $244 · 2023: $401 · 2024: $262 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524.04 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $411.20 | 2019-2022 | |
| Allergan, INC. | $377.47 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $282.10 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $206.29 | 2019-2025 | Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $176.97 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $132.32 | 2022-2023 | Qelbree |
| Axsome Therapeutics, INC. | $105.82 | 2023-2024 | Auvelity |
| Lundbeck LLC | $99.23 | 2019-2021 | |
| Alkermes, INC. | $98.57 | 2021-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $91.99 | 2022-2025 | Trintellix |
| Corium, LLC | $61.57 | 2022-2024 | Azstarys |
| Neurocrine Biosciences, INC. | $53.51 | 2025 | |
| Avanir Pharmaceuticals, INC. | $36.97 | 2022 | |
| Ironshore Pharmaceuticals INC. | $29.29 | 2023-2024 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26.98 | 2025 | Cobenfy |
| Biogen, INC. | $22.81 | 2025 | Zurzuvae |
| Alfasigma USA, INC. | $17.10 | 2020 | |
| Vertical Pharmaceuticals, LLC | $17.03 | 2025 | Relexxii |
| Tris Pharma INC | $16.72 | 2023 | Dyanavel Xr |
| Neos Therapeutics, LP | $15.47 | 2019 | |
| Orexo US, INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayashree John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.